📊 ABVC Key Takeaways
Is Abvc Biopharma, Inc.. (ABVC) a Good Investment?
ABVC Biopharma is a pre-revenue stage biotech company with severe operational losses, negative free cash flow of -$3.0M, and critically low liquidity (0.41x current ratio). The company is burning cash rapidly with minimal revenue generation ($296K, down 41.9% YoY), raising existential solvency concerns without near-term revenue inflection or significant capital raises.
ABVC Biopharma’s fundamentals are very weak: revenue is declining, operating losses remain extreme relative to its revenue base, and the business is consuming cash with negative operating and free cash flow. While leverage is low and the balance sheet is not heavily debt-funded, the very weak liquidity position and continued cash burn make the growth profile low quality and increase financing risk.
Why Buy Abvc Biopharma, Inc.. Stock? ABVC Key Strengths
- Conservative debt structure with low leverage (0.01x Debt/Equity ratio)
- Positive gross margin of 268.9% on product sales suggests pricing power when revenue scales
- Stockholders' equity of $11.1M provides some balance sheet cushion relative to liabilities
- Low debt burden with minimal long-term debt relative to equity
- Positive gross profit indicates some monetizable revenue sources or non-core income support
- Asset base and equity remain above total liabilities, providing some balance sheet cushion
ABVC Stock Risks: Abvc Biopharma, Inc.. Investment Risks
- Critical liquidity crisis: Current ratio of 0.41x indicates inability to cover short-term obligations; cash of only $681.5K at current burn rate covers <3 months of operations
- Collapsing revenue trend with 41.9% YoY decline to $296K, indicating failed commercialization or product market fit issues
- Unsustainable cash burn of -$3.0M operating cash flow with negative FCF margin of -1016%, requiring immediate financing or operational restructuring
- Massive operating losses of -$7.2M and net loss of -$7.9M demonstrate pre-profitability with no clear path to breakeven
- Current ratio of 0.41x and cash of only $681.48K indicate significant near-term liquidity pressure
- Revenue declined 41.9% YoY, pointing to weak commercial traction and poor growth quality
- Operating loss of $7.15M and free cash flow of -$3.01M show the business is far from self-funding
Key Metrics to Watch
- Quarterly cash position and runway estimate
- Revenue trajectory and signs of pipeline product commercialization
- Operating cash burn rate and any cost reduction initiatives
- Capital raise announcements or financing activities
- Cash runway including quarterly operating cash burn
- Revenue growth consistency and improvement in operating loss margin
Abvc Biopharma, Inc.. (ABVC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ABVC Profit Margin, ROE & Profitability Analysis
ABVC vs Healthcare Sector: How Abvc Biopharma, Inc.. Compares
How Abvc Biopharma, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Abvc Biopharma, Inc.. Stock Overvalued? ABVC Valuation Analysis 2026
Based on fundamental analysis, Abvc Biopharma, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Abvc Biopharma, Inc.. Balance Sheet: ABVC Debt, Cash & Liquidity
ABVC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Abvc Biopharma, Inc..'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-0.42 indicates the company is currently unprofitable.
ABVC Revenue Growth, EPS Growth & YoY Performance
ABVC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $389.3K | -$394.8K | $-0.03 |
| Q2 2025 | $117.1K | -$942.3K | $-0.08 |
| Q1 2025 | $1.2K | -$842.1K | $-0.06 |
| Q3 2024 | $15.9K | -$186.6K | $-0.02 |
| Q2 2024 | $6.1K | N/A | $-0.09 |
| Q1 2024 | $1.2K | -$1.8M | $-0.40 |
| Q3 2023 | $15.9K | -$3.3M | $-0.82 |
| Q2 2023 | $6.1K | -$1.9M | $-0.59 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Abvc Biopharma, Inc.. Dividends, Buybacks & Capital Allocation
ABVC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Abvc Biopharma, Inc.. (CIK: 0001173313)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ABVC
What is the AI rating for ABVC?
Abvc Biopharma, Inc.. (ABVC) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 93% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ABVC's key strengths?
Claude: Conservative debt structure with low leverage (0.01x Debt/Equity ratio). Positive gross margin of 268.9% on product sales suggests pricing power when revenue scales. ChatGPT: Low debt burden with minimal long-term debt relative to equity. Positive gross profit indicates some monetizable revenue sources or non-core income support.
What are the risks of investing in ABVC?
Claude: Critical liquidity crisis: Current ratio of 0.41x indicates inability to cover short-term obligations; cash of only $681.5K at current burn rate covers <3 months of operations. Collapsing revenue trend with 41.9% YoY decline to $296K, indicating failed commercialization or product market fit issues. ChatGPT: Current ratio of 0.41x and cash of only $681.48K indicate significant near-term liquidity pressure. Revenue declined 41.9% YoY, pointing to weak commercial traction and poor growth quality.
What is ABVC's revenue and growth?
Abvc Biopharma, Inc.. reported revenue of $296.0K.
Does ABVC pay dividends?
Abvc Biopharma, Inc.. does not currently pay dividends.
Where can I find ABVC SEC filings?
Official SEC filings for Abvc Biopharma, Inc.. (CIK: 0001173313) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ABVC's EPS?
Abvc Biopharma, Inc.. has a diluted EPS of $-0.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ABVC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Abvc Biopharma, Inc.. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ABVC stock overvalued or undervalued?
Valuation metrics for ABVC: ROE of -71.2% (sector avg: 15%), net margin of -2,671.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ABVC stock in 2026?
Our dual AI analysis gives Abvc Biopharma, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ABVC's free cash flow?
Abvc Biopharma, Inc..'s operating cash flow is $-3.0M, with capital expenditures of $21.2K. FCF margin is -1,016.0%.
How does ABVC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,671.8% (avg: 12%), ROE -71.2% (avg: 15%), current ratio 0.41 (avg: 2).